Logo image of PRPH

PROPHASE LABS INC (PRPH) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:PRPH - US74345W1080 - Common Stock

0.3626 USD
-0.08 (-18.97%)
Last: 1/2/2026, 8:00:01 PM
0.1814 USD
-0.18 (-49.97%)
After Hours: 1/2/2026, 8:00:01 PM
Fundamental Rating

0

Overall PRPH gets a fundamental rating of 0 out of 10. We evaluated PRPH against 190 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PRPH have multiple concerns. PRPH does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PRPH had negative earnings in the past year.
PRPH had a negative operating cash flow in the past year.
In multiple years PRPH reported negative net income over the last 5 years.
PRPH had negative operating cash flow in 4 of the past 5 years.
PRPH Yearly Net Income VS EBIT VS OCF VS FCFPRPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M

1.2 Ratios

PRPH has a worse Return On Assets (-81.22%) than 73.96% of its industry peers.
Looking at the Return On Equity, with a value of -777.79%, PRPH is doing worse than 82.81% of the companies in the same industry.
Industry RankSector Rank
ROA -81.22%
ROE -777.79%
ROIC N/A
ROA(3y)-27.2%
ROA(5y)-16.24%
ROE(3y)-243.55%
ROE(5y)-147.96%
ROIC(3y)N/A
ROIC(5y)N/A
PRPH Yearly ROA, ROE, ROICPRPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

PRPH does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PRPH Yearly Profit, Operating, Gross MarginsPRPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 -400 -600

More info and screens

0

2. Health

2.1 Basic Checks

PRPH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRPH has more shares outstanding
Compared to 5 years ago, PRPH has more shares outstanding
Compared to 1 year ago, PRPH has a worse debt to assets ratio.
PRPH Yearly Shares OutstandingPRPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M 25M
PRPH Yearly Total Debt VS Total AssetsPRPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

PRPH has an Altman-Z score of -3.94. This is a bad value and indicates that PRPH is not financially healthy and even has some risk of bankruptcy.
PRPH has a Altman-Z score (-3.94) which is comparable to the rest of the industry.
PRPH has a Debt/Equity ratio of 0.74. This is a neutral value indicating PRPH is somewhat dependend on debt financing.
PRPH has a Debt to Equity ratio of 0.74. This is in the lower half of the industry: PRPH underperforms 69.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Altman-Z -3.94
ROIC/WACCN/A
WACC15.08%
PRPH Yearly LT Debt VS Equity VS FCFPRPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M

2.3 Liquidity

PRPH has a Current Ratio of 0.14. This is a bad value and indicates that PRPH is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.14, PRPH is doing worse than 95.31% of the companies in the same industry.
PRPH has a Quick Ratio of 0.14. This is a bad value and indicates that PRPH is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.14, PRPH is not doing good in the industry: 94.27% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.14
PRPH Yearly Current Assets VS Current LiabilitesPRPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

0

3. Growth

3.1 Past

PRPH shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -138.78%.
The Revenue for PRPH has decreased by -80.65% in the past year. This is quite bad
PRPH shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -7.32% yearly.
EPS 1Y (TTM)-138.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.33%
Revenue 1Y (TTM)-80.65%
Revenue growth 3Y-55.91%
Revenue growth 5Y-7.32%
Sales Q2Q%-71.93%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y97.56%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year64.06%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PRPH Yearly Revenue VS EstimatesPRPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
PRPH Yearly EPS VS EstimatesPRPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 0 10 -10 -20

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

PRPH reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year PRPH is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PRPH Price Earnings VS Forward Price EarningsPRPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PRPH Per share dataPRPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -5 -10 -15 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

PRPH does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

PROPHASE LABS INC

NASDAQ:PRPH (1/2/2026, 8:00:01 PM)

After market: 0.1814 -0.18 (-49.97%)

0.3626

-0.08 (-18.97%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-17 2025-11-17
Earnings (Next)03-30 2026-03-30/amc
Inst Owners5.25%
Inst Owner Change0%
Ins Owners5.75%
Ins Owner Change0%
Market Cap15.95M
Revenue(TTM)6.77M
Net Income(TTM)-53.36M
Analysts82.86
Price TargetN/A
Short Float %N/A
Short Ratio0.03
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-75.17%
Min Revenue beat(2)-84.79%
Max Revenue beat(2)-65.56%
Revenue beat(4)0
Avg Revenue beat(4)-89.42%
Min Revenue beat(4)-164.6%
Max Revenue beat(4)-42.74%
Revenue beat(8)0
Avg Revenue beat(8)-80.88%
Revenue beat(12)2
Avg Revenue beat(12)-55.26%
Revenue beat(16)6
Avg Revenue beat(16)-28.97%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 2.36
P/FCF N/A
P/OCF N/A
P/B 2.32
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-23.4
EYN/A
EPS(NY)-0.57
Fwd EYN/A
FCF(TTM)-0.24
FCFYN/A
OCF(TTM)-0.24
OCFYN/A
SpS0.15
BVpS0.16
TBVpS-0.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -81.22%
ROE -777.79%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-27.2%
ROA(5y)-16.24%
ROE(3y)-243.55%
ROE(5y)-147.96%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0.74
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 5.84%
Cap/Sales 3.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.14
Altman-Z -3.94
F-Score3
WACC15.08%
ROIC/WACCN/A
Cap/Depr(3y)44.05%
Cap/Depr(5y)127.73%
Cap/Sales(3y)7.51%
Cap/Sales(5y)7.91%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-138.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.33%
EPS Next Y97.56%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-80.65%
Revenue growth 3Y-55.91%
Revenue growth 5Y-7.32%
Sales Q2Q%-71.93%
Revenue Next Year64.06%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-82.04%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year166.17%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-3.44%
OCF growth 3YN/A
OCF growth 5YN/A

PROPHASE LABS INC / PRPH FAQ

What is the ChartMill fundamental rating of PROPHASE LABS INC (PRPH) stock?

ChartMill assigns a fundamental rating of 0 / 10 to PRPH.


What is the valuation status for PRPH stock?

ChartMill assigns a valuation rating of 0 / 10 to PROPHASE LABS INC (PRPH). This can be considered as Overvalued.


Can you provide the profitability details for PROPHASE LABS INC?

PROPHASE LABS INC (PRPH) has a profitability rating of 0 / 10.


What is the earnings growth outlook for PROPHASE LABS INC?

The Earnings per Share (EPS) of PROPHASE LABS INC (PRPH) is expected to grow by 97.56% in the next year.


How sustainable is the dividend of PROPHASE LABS INC (PRPH) stock?

The dividend rating of PROPHASE LABS INC (PRPH) is 0 / 10 and the dividend payout ratio is 0%.